Marinomed Biotech AG
MARI.VI · VIE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | -1.33 | -1.88 | 9.02 |
| FCF Yield | 0.00% | -10.50% | -6.42% | -4.45% |
| EV / EBITDA | -7.59 | -17.54 | -30.81 | -39.11 |
| Quality | ||||
| ROIC | -156.62% | -43.07% | -34.87% | -26.64% |
| Gross Margin | -89.91% | 12.45% | 18.98% | 12.25% |
| Cash Conversion Ratio | 0.67 | 0.81 | 0.83 | 1.15 |
| Growth | ||||
| Revenue 3-Year CAGR | -25.05% | -7.57% | 11.55% | 23.69% |
| Free Cash Flow Growth | 0.00% | 14.25% | 6.13% | 46.67% |
| Safety | ||||
| Net Debt / EBITDA | -3.87 | -5.30 | -4.50 | -2.80 |
| Interest Coverage | -0.89 | -3.71 | -2.29 | -2.75 |
| Efficiency | ||||
| Inventory Turnover | 16.76 | 7.94 | 5.85 | 9.93 |
| Cash Conversion Cycle | 23.15 | 71.21 | 117.49 | 116.46 |